Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers. Single and Multiple Dose, Open Label, Pharmacokinetics and Safety Study

Cosmo Technologies Ltd0 sites18 target enrollmentJuly 2015

ConditionsHealthy

InterventionsRifamycin SV-MMX® 600

DrugsRifamycin SV-MMX® 600

Overview

Phase: Phase 1
Intervention: Rifamycin SV-MMX® 600
Conditions: Healthy
Sponsor: Cosmo Technologies Ltd
Enrollment: 18
Primary Endpoint: Cmax
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The objective of the study was to evaluate the pharmacokinetics and the safety of rifamycin SV after single and multiple doses of Rifamycin SV-MMX® 600 mg tablets administered to male and female healthy subjects.

Registry

clinicaltrials.gov

Start Date

July 2015

End Date

August 2015

Last Updated

8 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Cosmo Technologies Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Informed consent: signed written informed consent before inclusion in the study
•Sex and Age: men and women, 18-55 year old inclusive
•Body Mass Index: 18.5-30 kgm2 inclusive
•Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position
•Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study
•Fertility (women only): women of non-child-bearing potential or in post-menopausal status for at least 1 year.
•For all female subjects, pregnancy test result had to be negative at screening and Day -1

Exclusion Criteria

•ECG 12-leads (supine position): clinically significant abnormalities
•Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study
•Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
•Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considered could affect the outcome of the study
•Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that could interfere with the aim of the study
•Medications: medications, including over the counter medications and herbal remedies, for 2 weeks before the start of the study
•Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval was calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
•Blood donation: blood donations for 3 months before this study
•Drug, alcohol, caffeine, tobacco: history of drug, alcohol (more than 1 drink a day for females and more than 2 drinks a day for males, defined according to the USDA Dietary Guidelines 2010), caffeine (more than 5 cups coffee/tea/day) or tobacco abuse (10 cigarettes a day)
•Abuse drug test: positive result at the drug test at screening or Day-1